Not many but Don Junior likely to benefit
Donald Trump on February 5 launched a website, branded with his name, in a purported effort to
help patients buy prescription drugs at lower prices.
This is its actual logo. Always classy!
But experts, watchdog groups, and Democratic lawmakers
said TrumpRx will
likely do little for consumers—or for the broader goal of bringing down
exorbitant medicine costs—while further enriching Big Pharma and
potentially lining the pockets of his eldest son, Donald
Trump Jr.
TrumpRx.gov, launched in partnership with pharmaceutical giants, points
users to direct-to-patient sales platforms hosted by drug companies to
facilitate the purchase of an extremely limited selection of medications. For
example, TrumpRx’s listing
for Farxiga links users to AstraZeneca Direct, where patients can pay
out of pocket for the type 2 diabetes medication.
Donald
Trump Jr. is on the board of BlinkRx, a prescription drug platform
that stands to benefit from the Trump administration’s promotion of
direct-to-patient medicine sales. In December, the president’s son reportedly met with top drug company executives and
administration officials responsible for regulating the pharmaceutical
industry—a gathering hosted by BlinkRx.
Frank Pallone Jr. (D-NJ), the top Democrat on the House
Energy and Commerce Committee, said in a statement Thursday that TrumpRx “not only
threatens patients’ health, safety, and privacy, but also likely
includes kickback schemes designed to enrich President Trump, his family, and
their friends.”
.jpg)












